SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively discussed due to escalating geopolitical tensions, specifically new tariff threats against European economies related to Greenland, which has led to declines in overnight futures and global markets. The community is sharply divided, with many anticipating a significant market pullback, while others view it as a "buy the dip" opportunity, recalling historical recoveries from similar tariff-induced sell-offs. This divergence creates intense debate over whether current events will lead to a deeper correction or are merely temporary volatility before further upside.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed tariff threats regarding Greenland trigger market volatility, with the community sharply divided between those anticipating a significant correction and "buy the dip" proponents. Investors are weighing escalating geopolitical tensions and rising treasury yields against historical market resilience and expectations for a robust tech earnings season.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst widespread discussion surrounding former President Trump's controversial geopolitical moves, specifically his asserted interest in Greenland and proposed tariffs on European allies, which many observers link to a past Nobel Peace Prize snub. Community perspectives are sharply divided, with intense debate on the potential market implications of these actions, reflecting broader concerns about global stability and U.S. foreign policy.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is trending due to a sharp price decline, which the community is hotly debating as either market manipulation around options expiration and a circulating short report, or broader ad-tech concerns like OpenAI's entry into advertising. Amid this volatility, bullish investors highlight AppLovin's robust AI-powered Axon platform and strong profitability as a compelling dip-buying opportunity, contrasting with those fearing continued weakness despite recent analyst upgrades.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF (UVIX) is seeing intense discussion as escalating geopolitical tensions, from US actions in Venezuela and Greenland to EU tariff disputes and potential escalations with Iran and China, fuel expectations for a market-wide fear spike. Traders are actively positioning for a major upward move in volatility, leveraging UVIX for short-term hedges while widely acknowledging its pronounced decay characteristics make it unsuitable for extended holding.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as reports surface that Chinese customs have blocked H200 chip shipments, causing suppliers to pause production and sparking immediate market uncertainty. While some investors are reacting to the dip, many in the community view this as a buying opportunity, citing NVIDIA's robust long-term demand for its advanced AI architectures like Blackwell and Rubin. This geopolitical tension underscores the complex landscape for AI chip sales, even as analysts largely maintain bullish outlooks on NVIDIA's foundational role in global AI infrastructure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high investor enthusiasm following international approvals for its Anktiva treatment in both lung and bladder cancers, notably a first-in-world non-chemo combo for lung cancer from Saudi Arabia. This significant progress, coupled with reported substantial revenue growth, is generating widespread community discussion about the company's transformative potential in oncology and fueling considerable short squeeze speculation due to high short interest. Investors are closely monitoring further global regulatory developments and anticipating a paradigm shift in cancer treatment as Dr. Patrick Soon-Shiong actively promotes the company's innovative "BioShield" platform.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to a recently executed term sheet for a joint venture with a Saudi industrial conglomerate to build a rare earth processing facility, which notably secures 100% offtake for its Tanbreez project. The community is highly engaged in discussions surrounding Greenland's strategic importance for critical minerals, anticipating further updates and potential significant catalysts from upcoming corporate communications. This reinforces CRML's position in global efforts to diversify strategic mineral supply chains.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MULN CRYPTO is trending due to a mix of strong skepticism and active promotion, with many users questioning its legitimacy and connection to the controversial Mullen Automotive stock, often cited as a past "scam." While some in the community label it "garbage" and warn of further losses, a dedicated segment is actively calling for accumulation and anticipating significant price surges for the "Mullen Army" token on the Solana network.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is drawing attention following recent developments in its pipeline, including the acquisition of VLX-1005 and ongoing progress for its lead anticoagulant, tecarfarin, notably through a collaboration with Abbott for pivotal trials. Community discussion is split between excitement over its potential in treating rare cardiovascular conditions and concerns regarding dilution and the need for substantial financing for upcoming clinical milestones. Its ultra-low float is also a key talking point, contributing to observed volatility and the potential for significant price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics NV (LVTX) announced on Friday that they have agreed to amend their previous share purchase agreement and lowered the initial cash consideration to be received by LAVA shareholders.As per the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.xoma.com/news-events/press-releases/detail/487/xoma-royalty-and-lava-therapeutics-announce-amendment-to">amended deal</a>, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. Shareholders will also receive a contingent value right (CVR) representing the right to certain cash payments, the companies said.This includes the previously announced rights to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out-license or sale of LAVA’s unpartnered programs, in addition to a new right to receive up to approximately $0.23 per CVR.LAVA and XOMA Royalty also agreed to amend LAVA’s minimum net-cash closing condition to be $24.5 million, compared to the previous minimum net-cash closing condition of $31.5 million. The amended agreement is in light of the most recent estimates of LAVA’s expected cash balance at closing, among other factors, the companies said. The proposed acquisition is expected to close in the fourth quarter of 2025, as announced previously.LAVA said that it expects to convene a meeting of shareholders to approve matters related to the deal with XOMA Royalty on November 7, after <a href="https://stocktwits.com/news-articles/markets/equity/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN">postponing</a> it from its previous date of September 30.Last month, LAVA canceled its shareholder meeting to consider and approve matters related to the proposed transaction with XOMA. XOMA first announced that it would acquire LAVA in August.<a href="https://stocktwits.com/symbol/LVTX">LAVA shares</a> fell 3% on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around LVTX stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:588/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_2_25_55_PM_png_0c5aac6302.webp" alt="LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="63"><figcaption>LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>While LVTX shares have gained 56% this year, XOMA stock has risen 30%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Equity

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.


Shares of LAVA Therapeutics (LVTX) declined 8% in the pre-market session on Tuesday after the company canceled the Extraordinary General Meeting of shareholders scheduled to occur today.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/30/3158434/0/en/LAVA-Therapeutics-to-Move-Extraordinary-General-Meeting-to-Early-November-2025.html">said</a> that it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation (XOMA). XOMA announced in August that it will acquire LAVA for between $1.16 and $1.24 per share in cash, in addition to a contingent value right per share. The deal is expected to close in the fourth quarter (Q4) of 2025.The company said on Tuesday that it is canceling the meeting to continue discussions with XOMA concerning its estimated cash forecast and the consideration payable to the company’s shareholders in the transaction.LAVA also noted that both parties remain committed to completing the transaction by the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LVTX">LVTX stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.“We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVA’s cash forecast in an effort to close this transaction in an expeditious manner,” said XOMA CEO Owen Hughes.LAVA said on Tuesday that it expects to reconvene the shareholder meeting by early November. The date will be ascertained at a later date, and shareholders who have voted will have to cast their votes again on the matters proposed, it added.LVTX stock is up 69% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/chainlink-swift-advance-blockchain-integration-for-ubs-tokenized-funds/chDD4dRR3Bj">Chainlink, Swift Advance Blockchain Integration For UBS Tokenized Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

The firm stated it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation. 

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX
LAVA Therapeutics NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LVTX News

LVTXLAVA Therapeutics NV